Fig. 1 · Structure

Documents & Downloads

Lappaconite HBr

Cat. No. A10515 CAS 97792-45-5
Lappaconite Hydrobromide is a kind of alkaloid extracted from Aconitum sinomontanum Nakai and has anti-inflammatory effects.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Lappaconite HBr Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Lappaconite HBr from 3 published references. In vitro models include THP-1 cells.

Lappaconite HBr In Vitro Studies

Lappaconite HBr was evaluated in THP-1 cells using a cellular thermal shift assay with DMSO as control. The assay indicated a direct targeting effect on NR1H3. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular thermal shift assessment of receptor targeting

Cell-based study · THP-1 cells [1]

THP-1 cells were treated with Lappaconite HBr and assessed using a cellular thermal shift assay with DMSO as control. The assay indicated a direct targeting effect on NR1H3.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The protein bands (J) and melt curve (K) of cellular thermal shift assay (CETSA) were used to assess the binding between LAH and NR1H3Reported result THP-1 cells; LAH (100 μM); subjected to heating across a temperature gradient from 40 °C to 60 °C: Lappaconitine hydrobromide (LAH) showed a direct targeting effect on nuclear receptor subfamily 1 group H member 3 (NR1H3).[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Method
treated
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: Lappaconite HBr; Compound label in the paper: Lappaconitine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cellular thermal shift assay (CETSA) and isothermal dose-response fingerprintCETSA (ITDRFCETSA) (S177); Fig. 6 legend (S464, S476)

The protein bands (J) and melt curve (K) of cellular thermal shift assay (CETSA) were used to assess the binding between LAH and NR1H3: The protein bands (J) and melt curve (K) of cellular thermal shift assay (CETSA) were used to assess the binding between LAH and NR1H3; comparator: DMSO (for control) — Materials and methods > Cellular thermal shift assay (CETSA) and isothermal dose-response fingerprintCETSA (ITDRFCETSA) (S177); Fig. 6 legend (S464, S476)

Lappaconite HBr In Vivo Studies

In female ICR mice with K562-associated bone pain, intraperitoneal Lappaconite significantly reduced spontaneous pain compared with the untreated K562 group, without completely alleviating it. Lappaconite also restored inclined plate balance that had declined in the K562 cells transplanted group. In outbred male rats with aconitine-induced arrhythmia, intravenous Lappaconite administered before aconitine showed an antiarrhythmic effect in comparison with control. [2,3]

Spontaneous pain reduction in a mouse bone pain model

Animal study · female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20) [2]

Female ICR mice with K562-associated bone pain received intraperitoneal Lappaconite. Treatment significantly reduced spontaneous pain compared with the untreated K562 group but did not completely alleviate pain.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
spontaneous pain scoringReported result the treatment with lappaconitine at 4 mg/kg on day 15, 17 and 19 reduced the spontaneous pain significantly compared to the untreated K562 group, but did not alleviate the pain completely[2]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
on day 15, day 17, and day 19 after cancer cell transplantation
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lappaconite 4 mg/kguntreated K562 groupthe treatment with lappaconitine at 4 mg/kg on day 15, 17 and 19 reduced the spontaneous pain significantly compared to the untreated K562 group, but did not alleviate the pain completely[2]
Lappaconite 4 mg/kg
Model: female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Lappaconite; Compound label in the paper: Lappaconitine

The paper names Lappaconite without stating the salt or form; not verified as the hydrobromide form supplied as A10515. No dose conversion or lot validation.

Materials and Methods > Animal model (S3, S4, S7, S8); Materials and Methods > Lappaconitine treatment (S10); Materials and Methods > Pain behavior scoring (S11); Results > Pain behavior scoring (S44)

spontaneous pain scoring: spontaneous pain scoring; comparator: untreated K562 group — Materials and Methods > Pain behavior scoring (S11); Results > Pain behavior scoring (S44)

Lappaconite 4 mg/kg · Materials and Methods > Lappaconitine treatment (S10); Results > Pain behavior scoring (S44)

Antiarrhythmic effect in an aconitine rat model

Animal study · outbred male rats; aconitine model of arrhythmia [3]

Outbred male rats received intravenous Lappaconite before aconitine administration in an arrhythmia model. An antiarrhythmic effect was reported in comparison with control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Antiarrhythmic effect (%)Antiarrhythmic effect (%) 0.05 mg/kg, iv: 90 %[3]

Conditions shared by the study groups

Route
intravenously
Treatment course
5 min before the administration of the aconitine solution
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lappaconite 0.05 mg/kgH2O, 0.2 mLAllapinin; Dose (mg/kg, iv): 0.05; 5 min before the administration of the aconitine solution; Antiarrhythmic effect (%): 90[3]
Lappaconite 0.05 mg/kg
Model: outbred male rats; aconitine model of arrhythmia
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Lappaconite; Compound label in the paper: Allapinin

The paper names Lappaconite without stating the salt or form; not verified as the hydrobromide form supplied as A10515. No dose conversion or lot validation.

Material and Methods > Antiarrhythmic activity study (S98, S99, S101, S103); Table 4 (T4.h1, T4.h2, T4.r1, T4.r15)

Antiarrhythmic effect (%): Antiarrhythmic effect (%); comparator: H2O, 0.2 mL — Material and Methods > Antiarrhythmic activity study (S103); Table 4 (T4.h2, T4.r15)

Lappaconite 0.05 mg/kg · Material and Methods > Antiarrhythmic activity study (S103); Table 4 (T4.h2, T4.r15)

Inclined Plate Balance in a Mouse Bone Pain Model

Animal study · female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20) [2]

Female ICR mice in a bone pain model received Lappaconite by intraperitoneal injection. Treatment restored inclined plate balance that had been markedly reduced in the K562 cells transplanted group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The loss-balance degree for the inclined plateReported result The degree that mice could maintain balance was reduced markedly after 9 days in the K562 cells transplanted group, which was restored by lappaconitine treatment on day 15, 17 and 19[2]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
on day 15, day 17, and day 19 after cancer cell transplantation
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lappaconite 4 mg/kgK562 cells transplanted groupThe degree that mice could maintain balance was reduced markedly after 9 days in the K562 cells transplanted group, which was restored by lappaconitine treatment on day 15, 17 and 19[2]
Lappaconite 4 mg/kg
Model: female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Lappaconite; Compound label in the paper: Lappaconitine

The paper names Lappaconite without stating the salt or form; not verified as the hydrobromide form supplied as A10515. No dose conversion or lot validation.

Materials and Methods > Animal model (S3, S4, S7, S8); Materials and Methods > Lappaconitine treatment (S10); Materials and Methods > Pain behavior scoring (S19); Results > Pain behavior scoring (S46)

The loss-balance degree for the inclined plate: The loss-balance degree for the inclined plate; comparator: K562 cells transplanted group — Materials and Methods > Pain behavior scoring (S19); Results > Pain behavior scoring (S46)

Lappaconite 4 mg/kg · Materials and Methods > Lappaconitine treatment (S10); Results > Pain behavior scoring (S46)

Specifications

Manufacturer Adooq Bioscience
CAS Number 97792-45-5
Formula C32H44N2O8.HBr
Molecular Weight 665.6
Synonyms Allapinine
SMILES
CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@]5([C@H]6OC)O)OC)O)OC)OC(=O)C7=CC=CC=C7NC(=O)C.Br

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 26 mg/mL (39.06 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Lappaconite HBr Research References

  1. [1] Lan Y, Zhong Q, Huang H, et al. Lappaconitine hydrobromide prevents NLRP3-GSDMD-mediated pyroptosis to alleviate sepsis-induced acute lung injury by enhancing NR1H3. J Pharm Anal (2026). PMID: 42502718 DOI: 10.1016/j.jpha.2026.101631 Source material
  2. [2] Zhu XC, Ge CT, Wang P, et al. Analgesic effects of lappaconitine in leukemia bone pain in a mouse model. PeerJ (2015). PMID: 26019998 DOI: 10.7717/peerj.936 Source material
  3. [3] Satbayeva EM, Zhumakova SS, Khaiitova MD, et al. Experimental study of local anesthetic and antiarrhythmic activities of fluorinated ethynylpiperidine derivatives. Braz J Med Biol Res (2024). PMID: 39082579 DOI: 10.1590/1414-431X2024e13429 Source material

Added to your cart

View Cart Checkout
Loading...